--- title: "QuidelOrtho | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 619.8 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285303997.md" datetime: "2026-05-06T03:24:24.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285303997.md) - [en](https://longbridge.com/en/news/285303997.md) - [zh-HK](https://longbridge.com/zh-HK/news/285303997.md) --- # QuidelOrtho | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 619.8 M Revenue: As of FY2026 Q1, the actual value is USD 619.8 M, missing the estimate of USD 659.18 M. EPS: As of FY2026 Q1, the actual value is USD -1.35, missing the estimate of USD -0.71. EBIT: As of FY2026 Q1, the actual value is USD -28.4 M. ### Financial Performance for Three Months Ended March 29, 2026 (vs. March 30, 2025) #### Total Revenue QuidelOrtho Corporation reported total revenue of $619.8 million for the first quarter of 2026, marking a decrease of 10.5% as reported and 12.6% in constant currency compared to $692.8 million in the prior year period. #### Segment Revenue - **Point of Care revenue** was $112.8 million, declining by 34.0% as reported and 34.6% in constant currency, primarily due to a significantly weaker respiratory season. - **Labs revenue** was $353.1 million, declining by 5.3% as reported and 7.6% in constant currency, mainly due to slower distributor sales in China and business disruption related to the Middle East conflict. - **Immunohematology revenue** was $138.3 million, growing by 7.6% as reported and 3.4% in constant currency, driven by growth in North America, China, and JPAC. - **Donor Screening revenue** was $7.8 million, decreasing by 39.1% as reported and 39.5% in constant currency, from $12.8 million in the prior year. - **Molecular Diagnostics revenue** was $7.8 million, an increase of 2.6% as reported but a decrease of 1.8% in constant currency, from $7.6 million in the prior year. #### Profitability Metrics - **GAAP net loss** was - $91.8 million, compared to - $12.7 million in the prior year period. - **GAAP operating loss** was - $31.8 million, compared to an operating income of $32.6 million in the prior year period. - **Adjusted EBITDA** was $108.7 million, compared to $159.8 million in the prior year period. - **Adjusted EBITDA margin** was 17.5%, down from 23.1% in the prior year period. #### Operational Costs - **Cost of sales, excluding amortization of intangibles**, increased to $356.0 million from $349.5 million. - **Selling, marketing and administrative expenses** increased to $199.3 million from $187.0 million. - **Research and development expenses** decreased to $44.9 million from $53.2 million. - **Amortization of intangible assets** was $46.8 million, down from $48.0 million. - **Restructuring, integration and other charges** decreased to $4.4 million from $16.1 million. - **Other operating expenses** decreased to $0.2 million from $6.4 million. - **Interest expense, net** increased to $51.1 million from $40.0 million. - **Loss before income taxes** was - $79.5 million, compared to - $8.8 million in the prior year period. - **Provision for income taxes** was $12.3 million, compared to $3.9 million in the prior year period. #### Cash Flow - **Cash used for operating activities** was - $33.0 million, compared to cash provided by operating activities of $65.6 million in the prior year period. - **Cash used for investing activities** was - $34.0 million, compared to - $56.2 million in the prior year period. - **Cash provided by financing activities** was $37.6 million, compared to $17.6 million in the prior year period. ### Full-Year 2026 Financial Guidance (Updated as of May 5, 2026) QuidelOrtho Corporation updated its full-year 2026 financial guidance, anticipating total revenues between $2.70 billion and $2.75 billion, a reduction from the previous range of $2.7 billion to $2.9 billion. Adjusted EBITDA is now projected to be $615 million to $630 million with a 23% adjusted EBITDA margin, both lower than prior estimates. Free cash flow guidance was also revised downward to $100 million to $120 million from $120 million to $160 million previously. ### Related Stocks - [QDEL.US](https://longbridge.com/en/quote/QDEL.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Acenta Group delays Q1 interim report release to May 29, 2026](https://longbridge.com/en/news/287031560.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)